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Objective: Vitamin D is involved in brain health and function. Our objective was
to determine whether the serum 25-hydroxyvitamin D (25OHD) concentration was
associated with delirium in a case-control study of geriatric inpatients.
Methods: Sixty cases with delirium (mean ± SD, 84.8 ± 5.7years; 58.3% female)
and 180 age- and gender-matched controls were enrolled in a geriatric acute care
unit between 2012 and 2014. The diagnosis of delirium was made using the
Confusion Assessment Method. Hypovitaminosis D was defined using consecutively
the consensual threshold value of 50 nmol/L and a threshold value calculated
from a sensitivity-specificity analysis. Age, gender, number of acute diseases, use
of psychoactive drugs, season of testing, and serum concentrations of calcium,
parathyroid hormone, creatinine, albumin, TSH, vitamin B9 and vitamin B12 were used
as potential confounders.
Results: The 60 cases with delirium exhibited lower 25OHD concentration than 180
matched controls (35.4 ± 30.0 nmol/L vs. 45.9 ± 34.5 nmol/L, p = 0.035). Increased
25OHD concentration was associated with a decrease in delirium prevalence (OR= 0.99
[95CI: 0.98–0.99] per nmol/L of 25OHD, p = 0.038). The concentration distinguishing
between cases and controls with the best sensitivity-specificity was found between 29.5
and 30.5 nmol/L. The regression models showed that delirium was associated with
hypovitaminosis D defined either as 25OHD ≤ 50 nmol/L (OR = 2.37 [95CI: 1.07–5.25],
p = 0.034) or as 25OHD ≤ 30 nmol/L (OR = 2.66 [95 CI: 1.30–5.45], p = 0.008).
Conclusions: Decreased serum 25OHD concentrations were associated with delirium
among acute geriatric inpatients. The threshold concentration to differentiate between
cases and controls was around 30 nmol/L.
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INTRODUCTION
Clinical importance of hypovitaminosis D is linked to its high
prevalence, estimated at more than one billion people around the
word (1), and its health manifestations. Vitamin D is classically
known for its regulatory function in phosphocalcic metabolism
(2). A growing number of studies have also reported non-bone
effects of vitamin D in the past decade, especially on brain health
and function (3–5).
Hypovitaminosis D has been repeatedly associated with
neurocognition (6), particularly with major neurocognitive
disorders (7, 8) and accelerated cognitive decline (8, 9).
However, epidemiological associations reported thus far mainly
implied chronic neurocognitive disorders. In contrast, acute
neurocognitive disorders such as delirium were only scarcely
examined in this context.
Delirium is an acute neurocognitive disorder leading to
greater morbidity (pressure ulcers, infectious diseases, fall
risk, disability), complicated care course (prolonged hospital
stays, more frequent readmissions, increased healthcare costs),
and greater mid-term mortality (10–12). Pathophysiology of
delirium remains not fully elucidated. Some risk factors are well
identified, including the advance in age, male gender, history
of chronic neurocognitive disorders or psychiatric conditions
(11). However, these risk factors are unchangeable and cannot
be targeted to prevent delirium. Thus, potential changeable risk
factors are the matter of extensive research. Several hypotheses
are proposed, mainly based on biological imbalance within the
central nervous system (11). Considering the neurocognitive
effects of vitamin D, we hypothesized that hypovitaminosis D
could participate to the onset of delirium among older adults.
The aim of the present study was to determine whether serum
25-hydroxyvitamin D (25OHD) concentration was associated




We conducted a unicentric case-control study (1 case with
delirium for 3 controls without delirium) in the geriatric acute
care unit of the University Hospital of Angers, France, between
2012 and 2014. At the admission into the unit, participants
received standardized clinical and neuropsychological
assessments together with a blood test. The study was approved
by the local ethics committee and the Commission nationale
informatique et libertés (number 1408714).
Participants
All patients aged 70 years and older consecutively admitted
between 2012 and 2014 in the unit were considered for inclusion
in the study. Inclusion criterion for cases was the diagnosis of
delirium according to the Confusion AssessmentMethod (CAM)
(13). Controls exhibiting no diagnosis of delirium according
to the CAM were matched by age and gender (ratio 3:1). All
participants were affiliated to the French social insurance.
Data Collection
Delirium
Delirium was identified using the CAM (13), a standardized
tool aiming to screening for delirium. A senior physician
assessed four main criteria (a) acute onset and fluctuating course,
(b) inattention, (c) disorganized thinking, (d) altered level of
consciousness. Delirium was retained when criteria (a) and
(b) associated to criteria (c) and/or (d) were retrieved. This
assessment is quick and easy to use with good metrological
performance (13, 14).
Serum 25-hydroxyvitamin D Concentration
Serum concentrations of 25OHD effectively reflect the stock of
vitamin D in the body. Serum concentrations of 25OHD were
measured at the time of the CAM test by radioimmunoassay
(DiaSorin Inc., Stillwater, MN) in nmol/L (to convert to ng/mL,
divide by 2.496). With this method, there is no interference with
lipids, which is often observed in other non-chromatographic
assays of 25OHD. The intra- and interassay precision were 5.2
and 11.3%, respectively. Hypovitaminosis D was successively
defined using either the consensual threshold value of 50 nmol/L
according to the World Health Organization and the National
Institutes of Health definitions, or using a threshold value
calculated from a sensitivity-specificity analysis to best fit the
studied group.
Covariates
Age, gender, number of acute diseases, use of psychoactive
drugs, season of testing, serum concentrations of calcium,
parathyroid hormone, creatinine, albumin, thyroid-stimulating
hormone (TSH), vitamins B9 and B12 were used as potential
confounders. The number of acute diseases was assessed by a
senior physician at the admission. Using psychoactive drugs (i.e.,
antidepressants or neuroleptics or anxiolytics) were determined
from drug prescriptions at the admission. The season of testing
were categorized as follows: Spring from March 21 to June
20, Summer from June 21 to September 20, Autumn from
September 21 to December 20, and Winter from December
21 to March 20. All blood samples were analyzed using
standardized laboratory methods at the University Hospital of
Angers, France.
Number of Participants
Because the main objective of the study was descriptive, no
calculation of number of subjects was required. However, to
match a normal distribution of the data and to use parametric
statistical tests, at least 30 participants were required in each
group (i.e., n= 30 participants with delirium and n= 30 controls
at least). To improve the power of the study, we chose to triple
the number of controls (i.e., 3 controls per 1 case).
Statistics
The participants’ characteristics were summarized using means
and standard deviations (SD) or frequencies and percentages,
as appropriate. Normality of data distribution was checked
using skewness-kurtosis test. As the number of observations was
higher than 40, comparisons were not affected by the shape of
Frontiers in Neurology | www.frontiersin.org 2 September 2020 | Volume 11 | Article 1034
Chouët et al. Vitamin D and Delirium
the error distribution and no transform was applied (15). Firstly,
comparisons between cases with delirium and controls without
delirium were performed using Student’s t-test or the Chi-square
test, as appropriate. Secondly, the serum 25OHD threshold
value that best distinguished between cases and controls was
determined by sensitivity analysis. Thirdly, a multiple logistic
regression was used to examine the association between
delirium (dependent variable) and serum 25OHD (independent
variable), while adjusting for potential confounders. Finally,
similar logistic models were used to examine the association
between delirium and hypovitaminosis D defined either
using the consensual threshold value of 50 nmol/L or
using the threshold value calculated with the sensitivity
analysis. P-values < 0.05 were considered significant. All
statistics were performed using SPSS (v19.0, IBM Corporation,
Chicago, IL).
RESULTS
Sixty cases with delirium (mean ± SD, 84.8 ± 5.7years; 58.3%
female) and 180 controls without delirium (84.8 ± 5.7 years;
58.3% female) were included in the study. The mean serum
25OHD concentration was 43.3 ± 33.7 nmol/L, and 67.5% of
the studied group exhibited hypovitaminosis D ≤ 50 nmol/L.
Serum 25OHD concentration was lower among cases compared
to controls (respectively, 35.4 ± 30.0 nmol/L vs. 45.9 ± 34.5
nmol/L, p = 0.035), and hypovitaminosis D ≤ 50 nmol/L was
alsomore frequent among cases compared to controls (p= 0.039)
(Table 1).
Multiple logistic regression models showed that the increase
in serum 25OHD was inversely associated to delirium (OR =
0.989 [95% confidence interval (CI): 0.979–0.999] by nmol/L
of 25OHD, p = 0.038), even after adjusting for potential
confounders (OR = 0.988 [95CI: 0.975–0.999] by nmol/L of
25OHD, p= 0.047) (Table 2).
The best compromise between sensitivity and specificity to
predict delirium was calculated for a 25OHD threshold between
29.5 nmol/L (Se = 0.60, Sp = 0.37) and 30.5 nmol/L (Se = 0.58,
Sp= 0.35).
Hypovitaminosis D was associated with delirium whether
using the consensual threshold of 50 nmol/L (OR = 2.37
[95CI: 1.07–5.25], p = 0.034) or using the calculated threshold
of 30 nmol/L (OR = 2.66 [95CI: 1.30–5.45], p = 0.008)
(Table 3). Increased number of acute diseases and serum albumin
concentration were also associated with delirium (Tables 2, 3).
DISCUSSION
Delirium was associated with decreased 25OHD concentrations
among older adults hospitalized in geriatric acute care
unit, independently of all studied potential confounders.
Hypovitaminosis D (defined either by the consensual threshold
of 50 nmol/L or by a population-based threshold of 30 nmol/L)
was associated with delirium.
Our results are in accordance with the scarce previous
literature. Ford et al. found hypovitaminosis D (ie, insufficiency
TABLE 1 | Participants’ characteristics and comparisons between cases with










Clinical and demographical measures
Age, years 84.8 ± 5.7 84.8 ± 5.7 84.8 ± 5.7 1.000




8.5 ± 4.6 9.8 ± 4.5 8.1 ± 4.6 0.012
Use of psychoactive
drugs, n (%)
95 (39.7) 27 (45.0) 68 (38.0) 0.337
Season of testing
Spring, n (%) 58 (24.2) 14 (23.3) 44 (24.4) 0.648
Summer, n (%) 50 (20.8) 10 (16.7) 40 (22.2)
Autumn, n (%) 73 (30.4) 18 (30.0) 55 (30.6)
Winter, n (%) 59 (24.6) 18 (30.0) 41 (22.8)
Serum measures
25OHD, nmol/L 43.3 ± 33.7 35.4 ± 30.0 45.9 ± 34.5 0.035
Hypovitaminosis
D*, n (%)
162 (67.5) 47 (78.3) 115 (63.9) 0.039
Calcium, mmol/L 2.26 ± 1.15 2.26 ± 0.14 2.26 ± 0.15 0.866
Parathyroid
hormone, pg/mL
43.2 ± 35.4 46.0 ± 22.6 42.3 ± 38.7 0.498
Creatinine, µmol/L 94.0 ± 59.1 94.8 ± 63.1 93.8 ± 57.9 0.907
Albumin, g/L 34.1 ± 5.5 35.5 ± 5.5 33.6 ± 5.5 0.023
TSH, mUI/L 1.70 ± 1.79 1.84 ± 1.69 1.66 ± 1.82 0.511
Vitamin B9, µg/L 6.7 ± 6.1 6.6 ± 4.3 6.7 ± 6.6 0.904
Vitamin B12, ng/L 447.3 ± 311.7 453.1 ± 234.3 445.4 ± 333.9 0.873
Quantitative data are presented as mean ± standard deviation; 25OHD, 25-
hydroxyvitamin D; TSH, thyroid-stimulating hormone; *serum 25-hydroxyvitamin D ≤50
nmol/L; p-value significant <0.05 indicated in bold.
<75 nmol/L or deficiency <25 nmol/L) in 66% of people
diagnosed with delirium from three Canadian university
hospitals (12). Similarly, in a cohort of more than 4,000 patients,
Quraishi et al. reported that serum 25OHD concentration <25
nmol/L prior to hospitalization was associated with an increased
risk of delirium during the hospital stay (16), which suggested
that the vitamin D status could be a changeable risk factor
for delirium acquired during hospitalization. In contrast, such
association was not found within intensive care units (17).
The divergence could be explained by the initial severity of
the acute medical problem and by the different levels of care
provided, which may overpass the effect of hypovitaminosis
D on delirium risk, if any. Compared to previous literature,
we provide here the first case-control study on this issue to
our knowledge, which allowed us to calculate the threshold of
serum 25HOD corresponding specifically to the onset of delirium
among geriatric inpatients.
Delirium is an acute cognitive dysfunction. Most previous
studies reported that hypovitaminosis D could be associated with
increased risks of Alzheimer disease (AD) and related disorders
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TABLE 2 | Univariate and multiple logistic regression models assessing the
cross-sectional association between serum 25-hydroxyvitamin D concentration
(independent variable) and the diagnosis of delirium (dependent variable) after
adjustment for potential confounders* (n = 240).
Delirium
























































































25OHD, 25-hydroxyvitamin D; CI, confidence interval; OR, odds ratio; TSH, thyroid-
stimulating hormone; *adjusted on season of testing without significant effect (OR = 1.00
[95CI: 0.73–1.35], p = 0.976); OR significant (i.e., p < 0.05) indicated in bold.
(18, 19). One meta-analysis found a 2.4-fold higher risk of
cognitive dysfunction among people with hypovitaminosis D
compared to those without hypovitaminosis D (7). Moreover,
patients with AD have lower serum 25OHD concentrations
compared to those without AD (19). Such association was found
both in the severe (20) but also in the prodromal stages of AD
(21), just as if hypovitaminosis D contributed to the process
of neurodegenerative dementia. Consistently, cohort studies
confirmed that hypovitaminosis D precedes and predicts the
onset of AD (7, 9). As a consequence, an international expert
consensus concluded that hypovitaminosis D increased the risk
of cognitive decline and dementia in older patients (8).
Mechanisms linking hypovitaminosis D to delirium are not
fully elucidated. Vitamin D receptors were found in neurons
and glial cells from brain areas that are essential to cognitive
function (temporal cingular and orbital cortex, thalamus,
nucleus accumbens, stria terminalis and amygdala) (22). By
modifying the gene expression of various proteins, vitamin D
modulates some effects that could influence neurophysiology and
TABLE 3 | Multiple logistic regression models* assessing the cross-sectional
association between delirium and hypovitaminosis D defined using (A) consensual
threshold of 50 nmol/L or (B) calculated threshold of 30 nmol/L (n = 240).
Delirium



























































































25OHD, 25-hydroxyvitamin D; CI, confidence interval; OR, odds ratio; TSH, thyroid-
stimulating hormone; *adjusted on season of testing without significant effect (OR = 1.02
[95CI: 0.75–1.39] with p= 0.886 in Model A; OR= 1.01 [95CI: 0.74–1.37] with p= 0.956
in Model B); OR significant (i.e., p < 0.05) indicated in bold.
neuroprotection (4). With regards to neurophysiology, vitamin
D regulates neurotrophic agents and controls cell differentiation
and maturation (23). Vitamin D also regulates the gene
expression of various neurotransmitters including acetylcholine,
dopamine and serotonin (6). With regards to neuroprotection,
vitamin D limits inflammatory changes associated with aging in
hippocampus (24), prevents the accumulation of Aβ peptides
by stimulating phagocytosis (25) and blood-brain barrier efflux
transport (26). Moreover, vitamin D is involved in calcium
homeostasis by regulating calcium channels (27). Vitamin D
also protects the brain against glutamate toxicity (28) through
anti-oxidant and anti-ischemic effects. As a consequence,
hypovitaminosis D is associated with changes in brain volume
(29), vascularization (30) and metabolism (31); all changes
that may explain the greater risk of delirium in the case of
hypovitaminosis D. Nevertheless, causality could not be deducted
from our observational study, and delirium may actually
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be the expression of an altered cognitive status responsible
for hypovitaminosis D because of disability and subsequent
decreased food intakes and sun exposure.
We found a positive association between the number of
acute diseases and delirium. This association could be explained
on the one hand by the multifactorial origin of the delirium;
most patients with delirium having multiple triggering factors
independently of any previous major neurocognitive disorder
(32). On the other hand, it is also possible that acute diseases were
the consequences of delirium (11).
Our study presents some limitations. First, the case-control
design of our study is less robust than a prospective longitudinal
cohort study. Second, the CAM is a screening rather than
a diagnostic tool despite very high metrological performance
(14). Because of its 99% specificity (14), we assume all
included patients effectively suffered from delirium. Third, our
results cannot be generalized to all older adults due to the
unicentric recruitment and the relatively limited number of
participants. Fourth, although we were able to control for
important characteristics that could modify the associations,
residual potential confounders might still be present such as
the ApoE genotype. Fifth, because 90% of frail elderly patients
admitted into our hospital geriatric acute care unit suffer
from major neurocognitive disorders, we did not use chronic
neurocognitive disorders as a potential confounder here. Last,
the use of an observational design precludes from inferring any
causal inference.
CONCLUSIONS
We were able to report an association between serum 25OHD
concentration and delirium in older adults hospitalized in a
geriatric acute care unit, especially below 30 nmol/L. This result
should be confirmed in larger longitudinal studies, preferentially
on a variety of adult populations. Nevertheless, it provides new
clues for better understanding the involvement of vitamin D in
neurocognitive decline and acute failure illustrated by delirium. It
also provides a scientific basis for conducting clinical trials to test
the efficacy of vitamin D supplementation to prevent or improve
the prognosis of delirium in older patients with initial serum
25OHD < 30 nmol/L.
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